Abbott Integrates Precision Oncology Tests into Flatiron's OncoEMR Platform

Expanded access to Abbott's cancer tests across 1,600 community care centers and 4,700 providers

Mar. 30, 2026 at 2:20pm

Got story updates? Submit your updates here. ›

Abbott, a global healthcare company, has integrated its comprehensive Precision Oncology portfolio into Flatiron Health's OncoEMR, a cloud-based Electronic Medical Record (EMR) platform. This integration allows oncology providers to digitally order Abbott's tests, including the Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard, and receive status updates and results directly within their existing OncoEMR clinical workflow. The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care.

Why it matters

This integration aims to make it easier for clinicians to access the right information at the right moment of care, reducing friction in the workflow and helping providers move faster from test ordering to treatment decisions. This is particularly important for community oncology practices, where most cancer care is delivered, as it removes a key barrier to accessing Abbott's portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care.

The details

Through this integration, oncology providers can now digitally order Abbott's tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. The available Abbott tests include the Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care.

  • The integration was announced on March 30, 2026.

The players

Abbott

A global healthcare company that helps people live more fully at all stages of life, with leading businesses and products in diagnostics, medical devices, nutritionals, and branded generic medicines.

Flatiron Health

A healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Flatiron Health is an independent affiliate of the Roche Group.

OncoEMR

Flatiron's cloud-based Electronic Medical Record (EMR) platform used by oncology providers.

Quincy Weatherspoon

VP and GM of Point of Care Solutions at Flatiron Health.

Brian Baranick

Vice president of Precision Oncology at Abbott.

Got photos? Submit your photos here. ›

What they’re saying

“We're focused on making it easier for clinicians to access the right information at the right moment of care. By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care.”

— Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health

“For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care.”

— Brian Baranick, Vice president, Precision Oncology, Abbott

What’s next

The integration of Abbott's Precision Oncology portfolio into Flatiron's OncoEMR platform is expected to expand access to these tests across Flatiron's network of community cancer care centers, helping to improve the workflow and decision-making process for oncology providers.

The takeaway

This integration between Abbott and Flatiron Health represents a significant step forward in bringing more connected, data-driven cancer care to the point of care, particularly for community oncology practices where the majority of cancer patients receive treatment. By streamlining access to Abbott's comprehensive Precision Oncology portfolio, this collaboration aims to accelerate informed treatment decisions and enable more personalized patient care.